NCT05111080 is a clinical trial in PTEN Gene Deletion, sponsored by Assiut University.

Who is sponsoring NCT05111080?

NCT05111080 is sponsored by Assiut University.

What condition does NCT05111080 study?

NCT05111080 studies PTEN Gene Deletion.

Is NCT05111080 still recruiting?

NCT05111080 is currently status unknown. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT05111080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Partial PTEN Deletion in Breast Cancer

Status unknown Last updated 8 November 2021

What this trial tests

trial in PTEN Gene Deletion in 40 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
30 December 2024

30 January 2025

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 November 2021
Primary completion	30 December 2024
Estimated completion	30 January 2025

Conditions studied

PTEN Gene Deletion — all drugs for PTEN Gene Deletion →

Sponsor

Assiut University

Who can join

20 and older, female only, with PTEN Gene Deletion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Detection of chromosome 10q23 deletion including PTEN locus in breast cancer patients. * Correlation between PTEN deletion and clinicopathological characteristics in breast cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05111080 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05111080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing